Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication

被引:33
|
作者
Berthoux, L [1 ]
Péchoux, C [1 ]
Darlix, JL [1 ]
机构
[1] Ecole Normale Super, INSERM, Unite Virol Humaine, LaboRetro, F-69364 Lyon 07, France
关键词
D O I
10.1128/JVI.73.12.10000-10009.1999
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human immunodeficiency virus type 1 nucleocapsid protein is a major structural component of the virion core and a key factor involved in proviral DNA synthesis and virus formation. 2,2'-Dithiobenzamides (DIBA-1) and related compounds that are inhibitors of NCp7 are thought to eject zinc ions from NCp7 zinc fingers, inhibiting the maturation of virion proteins. Here, we show that the presence of DIBA-1 at the time of virus formation causes morphological malformations of the virus and reduces proviral DNA synthesis. Thus, it seems that DIBA-1 is responsible for a "core-freezing effect," as shown by electron microscopy analyses. DIBA-1 can also directly interfere with the fate of the newly made proviral DNA in a manner independent of its effects on virion core formation. These data strongly suggest that nueleocapsid protein is a prime target for new compounds aimed at inhibiting human immunodeficiency virus and other retroviruses.
引用
收藏
页码:10000 / 10009
页数:10
相关论文
共 50 条
  • [1] The Anti-Angiogenic Effects of Anti-Human Immunodeficiency Virus Drugs
    Barillari, Giovanni
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [2] Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages
    Ewart, GD
    Nasr, N
    Naif, H
    Cox, GB
    Cunningham, AL
    Gage, PW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) : 2325 - 2330
  • [3] Neuroprotective and anti-human immunodeficiency virus, activity of minocycline
    Zink, MC
    Uhrlaub, J
    DeWitt, J
    Voelker, T
    Bullock, B
    Mankowski, J
    Tarwater, P
    Clements, J
    Barber, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (16): : 2003 - 2011
  • [4] ANTI-HUMAN IMMUNODEFICIENCY VIRUS PHENOLICS FROM LICORICE
    HATANO, T
    YASUHARA, T
    MIYAMOTO, K
    OKUDA, T
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 1988, 36 (06) : 2286 - 2288
  • [5] Anti-human immunodeficiency virus drug combination strategies
    Vandamme, AM
    Van Vaerenbergh, K
    De Clercq, E
    [J]. ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1998, 9 (03): : 187 - 203
  • [6] RADIOIMMUNOASSAY FOR RETROVIR, AN ANTI-HUMAN IMMUNODEFICIENCY VIRUS DRUG
    QUINN, RP
    ORBAN, B
    TADEPALLI, S
    [J]. JOURNAL OF IMMUNOASSAY, 1989, 10 (2-3): : 177 - 189
  • [7] Potent anti-feline immunodeficiency virus and anti-human immunodeficiency virus effect of IFN-tau
    Pontzer, CH
    Yamamoto, JK
    Bazer, FW
    Ott, TL
    Johnson, HM
    [J]. JOURNAL OF IMMUNOLOGY, 1997, 158 (09): : 4351 - 4357
  • [8] In vitro anti-human immunodeficiency virus activity of mangrove plants
    Premanathan, M
    Nakashima, H
    Kathiresan, K
    Rajendran, N
    Yamamoto, N
    [J]. INDIAN JOURNAL OF MEDICAL RESEARCH, 1996, 103 : 278 - 281
  • [9] AMINOSUGAR DERIVATIVES AS POTENTIAL ANTI-HUMAN IMMUNODEFICIENCY VIRUS AGENTS
    KARPAS, A
    FLEET, GWJ
    DWEK, RA
    PETURSSON, S
    NAMGOONG, SK
    RAMSDEN, NG
    JACOB, GS
    RADEMACHER, TW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (23) : 9229 - 9233
  • [10] Anti-human immunodeficiency virus activity of polyhydroxy fullerenes in vitro
    Schinazi, RF
    Chiang, LY
    Wilson, LJ
    Cagle, DW
    Hill, CL
    [J]. PROCEEDINGS OF THE SYMPOSIUM ON RECENT ADVANCES IN THE CHEMISTRY AND PHYSICS OF FULLERENES AND RELATED MATERIALS, VOL 4, 1997, 97 (14): : 357 - 360